Background: A mid-size pharmaceutical company was preparing to advance a late-stage asset in a chronic, specialist-led disease area. Epidemiological modeling pointed to a sizable addressable populati ...

Background: A global specialty pharmaceutical company was approaching the launch of a new chronic-therapy asset in a market characterized by heavy competition. The compound had strong clinical differ ...